Published in Oncoimmunology on October 29, 2015
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med (2017) 2.05
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
Up-Regulation of Claudin-6 in the Distal Lung Impacts Secondhand Smoke-Induced Inflammation. Int J Environ Res Public Health (2016) 0.75
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62
Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 2.58
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Hybrid antibodies can target sites for attack by T cells. Nature (1985) 2.36
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol (1987) 2.04
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol (2007) 1.95
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer (2005) 1.77
Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol (2015) 1.76
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol (2005) 1.64
Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development (2002) 1.51
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer (2007) 1.33
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology (2009) 1.28
Tight junctions containing claudin 4 and 6 are essential for blastocyst formation in preimplantation mouse embryos. Dev Biol (2007) 1.17
Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One (2013) 1.16
Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn (2001) 1.13
Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins. Am J Physiol Renal Physiol (2006) 1.13
Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J (1991) 1.13
Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun (2013) 1.12
Genetic targeting of the endoderm with claudin-6CreER. Dev Dyn (2008) 1.11
Bispecific antibodies rise again. Nat Rev Drug Discov (2014) 1.06
Blinatumomab: first global approval. Drugs (2015) 1.03
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer (2014) 1.00
Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol (2009) 0.98
Age-related changes of claudin expression in mouse liver, kidney, and pancreas. J Gerontol A Biol Sci Med Sci (2009) 0.92
Expression patterns of claudin family of tight junction membrane proteins in developing mouse submandibular gland. Dev Dyn (2004) 0.91
T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst (1987) 0.90
Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J Gastrointest Cancer (2009) 0.88
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer (2011) 0.87
Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma. Diagn Pathol (2013) 0.86
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res (1990) 0.86
Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors. Am J Surg Pathol (2012) 0.85
The distinct expression patterns of claudin-2, -6, and -11 between human gastric neoplasms and adjacent non-neoplastic tissues. Diagn Pathol (2013) 0.84
Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. Histopathology (2012) 0.84
NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer (2013) 0.81
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol (2015) 0.81
Twist is inversely associated with claudins in germ cell tumors of the testis. APMIS (2010) 0.80
Identification of circulating fetal cell markers by microarray analysis. Prenat Diagn (2012) 0.80